Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial
Status:
RECRUITING
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
The goal of this proof-of-concept clinical trial is to evaluate the initial safety, feasibility, and tolerability of the orexin mixed antagonist suvorexant in a sample of veteran adults with Major Depressive Disorder and elevated suicide risk. The main question it aims to answer is: Is Suvorexant safe, feasible, and tolerable for participants?
Participants will:
* Take Surovexant every day for four weeks (10mg in the first two weeks and 20mg in the second two weeks)
* Visit the medical center at the beginning of the study (week 1), after taking Suvorexant for two weeks (week 3) and following the full Suvorexant dose (week 5) for in-person assessments.
* Fill out self-report assessments (remotely) at week 2 (after one week of Suvorexant) and week 4 (after three weeks of Surovexant)